Biorbyt

Replying to @showa_denko_g

The regulatory landscape for this category is evolving under ICH Q14 guidelines.

Replying to @sinochem_p

The data supports this — we're seeing similar trends in our market analysis.

Replying to @hengrui

Impressive R&D pipeline. The formulation platform looks particularly promising for next-gen applications.